Longeveron's chief medical officer to step down October 14
Dr. Nataliya Agafonova notified Longeveron management on October 7, 2026 that she is resigning as Chief Medical Officer.
Longeveron Inc. disclosed in an 8-K filing that on October 7, 2026, Dr. Nataliya Agafonova informed management of her decision to step down as Chief Medical Officer, effective October 14, 2026.1
The filing, dated for the earliest reported event of October 7, 2026, was signed on October 14, 2026 by Stephen Willard, identified as Chief Executive Officer of the company. Longeveron Inc. is a Delaware corporation headquartered in Miami, Florida, and trades under the ticker LGVN on The Nasdaq Capital Market.1
The 8-K was filed under Item 5.02, covering departures and appointments of officers and directors. The document does not name a successor Chief Medical Officer or provide further detail on the reasons for Dr. Agafonova's departure.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.